Arca
Skip to content
Tools
Tools

FDPS: Farnesyl pyrophosphate synthase

Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones.

  • Drugs that act on it: 6
  • Approved: 6
  • In phases 1 to 3: 0
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on FDPS, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 6

Approved6

  • Zoledronic acid anhydrous
  • Alendronic acid
  • Risedronic acid
  • Ibandronic acid
  • Minodronic acid
  • Pamidronic acid

Phase 30

    Phase 20

      Phase 10

        Sponsors

        Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Farnesyl diphosphate synthase inhibitor.
        Zoledronic acid anhydrousApproved—Small moleculeInhibitor48
        Alendronic acidApprovedOrganonSmall moleculeInhibitor16
        Risedronic acidApprovedHanlim PharmSmall moleculeInhibitor4
        Ibandronic acidApprovedRocheSmall moleculeInhibitor2
        Minodronic acidApprovedAstellas PharmaSmall moleculeInhibitor0
        Pamidronic acidApproved—Small moleculeInhibitor0

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 21 in all, from ClinicalTrials.gov.
        Fighting Osteoporosis With Risedronate Co-Therapy During IncretinRisedronic acidPhase 3Not yet recruitingWake Forest University Health SciencesNov 17, 2026
        Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMDZoledronic acid anhydrousPhase 4Not yet recruitingSahlgrenska University HospitalAug 19, 2026
        Pharmacokinetics of Zoledronic Acid in Patients on DialysisZoledronic acid anhydrousPhase 1Not yet recruitingUniversity of Campinas, BrazilAug 3, 2026
        Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone MetastasesZoledronic acid anhydrousNot applicableNot yet recruitingWest China HospitalJul 7, 2026
        EFFICACY AND SAFETY OF ZOLEDRONATE VERSUS PLACEBO ON PAIN AT WEEK 12 IN PEDIATRIC PATIENTS WITH CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITISZoledronic acid anhydrousPhase 2Not yet recruitingAssistance Publique - Hôpitaux de ParisJun 25, 2026
        Phase Ib Trial of Injectable RAB001 for Knee OsteoarthritisAlendronic acidPhase 1Enrolling by invitationZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.Jun 17, 2026
        A Phase II Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral HeadAlendronic acidPhase 2Active, not recruitingZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.Mar 13, 2026
        Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and EfficacyRisedronic acidPhase 2Active, not recruitingHarbin Medical UniversityMar 13, 2026
        Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic AnemiaZoledronic acid anhydrousPhase 1 / Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, ChinaMar 13, 2026
        Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III OsteomyelitisAlendronic acidPhase 3RecruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineFeb 27, 2026
        The Comparison of Ibandronate and Zoledronic Acid After Denosumab DiscontinuationIbandronic acid, Zoledronic acid anhydrousPhase 4RecruitingNational Taiwan University HospitalFeb 12, 2026
        Zoledronate to Prevent Bone Health Complications in Pediatric Hematopoietic Stem Cell Transplant SurvivorsZoledronic acid anhydrousPhase 1RecruitingChildren's Hospital Medical Center, CincinnatiJan 29, 2026
        Step-down Therapy After Long-term Osteoporosis TreatmentZoledronic acid anhydrousPhase 4RecruitingNational Taiwan University HospitalDec 15, 2025
        Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing ChemoradiationAlendronic acidPhase 1 / Phase 2Not yet recruitingDr. Itay GoorAryehNov 24, 2025
        Small Trial of Alendronate Impact on the Reservoir of HIVAlendronic acidPhase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)Oct 15, 2025
        Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone MetastasesIbandronic acidPhase 2RecruitingKelly Fitzgerald, MDJun 29, 2025
        A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without FracturesAlendronic acidPhase 4RecruitingOdense University HospitalMar 7, 2025
        Clinical Efficacy of 1% Metformin and Alendronate Gel in Adjunct to Fibrin in Chronic PeriodontitisAlendronic acidPhase 4Active, not recruitingBahria UniversityMar 4, 2025
        Precision Medicine Approach for Osteoporosis - Follow Up StudyAlendronic acidPhase 4Enrolling by invitationPaul F NetzelFeb 20, 2024
        Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric SurgeryRisedronic acidPhase 3RecruitingWake Forest University Health SciencesJun 10, 2021
        Effects of Bisphosphonates on OI-Related Hearing LossRisedronic acidPhase 4RecruitingHospital for Special Surgery, New YorkNov 5, 2019

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Porokeratosis 9, multiple types0.64
        • Disseminated superficial actinic porokeratosis0.62
        • Plasma cell myeloma0.60
        • Bone Paget disease0.60
        • Prostate carcinoma0.59
        • Metastasis0.59
        • Hypercalcemia disease0.56
        • Cancer0.56

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1782, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P14324, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.